
The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression

This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer

The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe

TNBC is the most aggressive type of breast cancer and has historically been difficult to treat

The company has also opened its first dedicated genetic medicine facility in Indiana in the US

With a 10-day ceasefire between Israel and Lebanon in effect, oil prices are retreating from recent highs

The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study

Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need

The combination treatment showed a 35% reduction in the risk of disease progression

The five-year survival rate for metastatic breast cancer is 30%

The drug treatment is being evaluated in several ongoing phase 3 trials

The findings are based on Lilly’s phase 3 monarchE trial